Nektar Therapeutics (NKTR) Tops Q3 EPS by 2c
Tweet
Share
E-mail
Get Alerts NKTR Hot Sheet
Price: $67.63 +0.37%
Revenue Growth %: -11.4%
Financial Fact:
Total operating costs and expenses: 69.24M
Today's EPS Names:
ALZN, ASPU, USAU, More
Revenue Growth %: -11.4%
Financial Fact:
Total operating costs and expenses: 69.24M
Today's EPS Names:
ALZN, ASPU, USAU, More
Join SI Premium – FREE
Nektar Therapeutics (NASDAQ: NKTR) reported Q3 EPS of ($0.18), $0.02 better than the analyst estimate of ($0.20). Revenue for the quarter came in at $24.12 million versus the consensus estimate of $21.65 million.
For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UBS sees a negative catalyst ahead for Nike: Here’s what to watch
- Rosenblatt Reiterates Buy Rating on CoreWeave (CRWV)
- Empress Announces Agreement to Acquire Tongon Gold Stream and Secures Debt Financing
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
